Diabetes Cell Therapies Take Evasive Action
Procyon Technologies and Klearchos Papas are mentioned in a Nature Biotechnology article published in Feb 2022
Health Sciences Researchers Close In on Diabetes Solution
After hunting for decades, Drs. Klearchos Papas, Robert Johnson and Tom Loudovaris helped develop a bio-artificial pancreas at the University of Arizona Health Sciences. The team’s solution is composed of islet cells protected in a special oxygen-enabled pouch...Assessment of Islet Quality Pre-Transplant by Klearchos Papas, Ph.D.
At the invitation and request of the U.S. Food & Drug Administration (FDA), Klearchos Papas, Ph.D., presented on “Assessment of Islet Quality Pre-Transplant” at the advisory committee meeting of the Center for Biologics Evaluation and Research (CBER),...Procyon Technologies LLC and Novo Nordisk A/S to Collaborate on the Development of a Stem-Cell Based Therapy for Type 1 Diabetes
Procyon Technologies LLC today announced that it has entered into an exclusive research collaboration and license agreement with Novo Nordisk A/S to develop an implantable cell encapsulation device to be used in Novo Nordisk’s development of a novel therapy for Type 1 diabetes.